Real-time Estimate
Cboe BZX
11:06:08 2024-05-14 am EDT
5-day change
1st Jan Change
8.8
USD
+1.97%
+4.96%
+72.71%
Sales 2024 *
71.56M
Sales 2025 *
277M
Capitalization
5.97B
Net income 2024 *
-437M
Net income 2025 *
-307M
EV / Sales 2024 *
83.4
x
Net cash position
2024
*
-
Net cash position
2025
*
-
EV / Sales 2025 *
21.5
x P/E ratio 2024 *
-10.3
x
P/E ratio 2025 *
-17.1
x
Employees
628
Yield 2024 *
-
Yield 2025 *
-
Free-Float
22.36%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment
May. 07
MT
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
May. 07
CI
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline
May. 06
MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline
May. 03
MT
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types
May. 02
CI
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline
Apr. 30
MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating
Apr. 29
MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance
Apr. 29
MT
Transcript : ImmunityBio, Inc. - Special Call
Apr. 26
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Apr. 25
CI
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer
Apr. 23
MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday
Apr. 23
MT
Top Premarket Gainers
Apr. 23
MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva
Apr. 23
DJ
More news
IN DIRETTA DAI MERCATI: Netweek, Ence Energia, Enel, OVS, Sogefi, Telecom Italia, ASML, Novartis, Airbus, Apple, Nvidia, Boeing...
Apr. 23
C'est parti pour les publications de résultats à la chaîne
Apr. 23
En Direct des Marchés : Renault, SAP, Sanofi, TotalEnergies, Novartis, Legrand, Tapestry, OVH...
Apr. 23
EN DIRECTO DESDE LOS MERCADOS: Enagas, Ence Energia, Acerinox, Naturgy, Endesa, Telefónica, Novartis, Apple, Nvidia, Boeing...
Apr. 23
Bolsa de Madrid: Publicación consecutiva de resultados
Apr. 23
More news 1 day +6.28%
1 week +10.50%
Current month +8.01%
1 month +68.88%
3 months +104.02%
6 months +150.87%
Current year +71.91%
More quotes
Managers
Title Age Since
Chief Executive Officer
55
20-09-30
Founder
71
14-11-30
Director of Finance/CFO
46
19-06-30
Members of the board
Title Age Since
Founder
71
14-11-30
Director/Board Member
58
19-05-31
Director/Board Member
78
21-02-23
More insiders
Date
Price
Change
Volume
24-05-14
8.68
+0.58%
3 057 467
24-05-13
8.63
+6.28%
6,184,298
24-05-10
8.12
+0.74%
4,112,241
24-05-09
8.06
+1.77%
4,499,599
24-05-08
7.92
-4.12%
5,212,663
Delayed Quote
Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotes
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
More about the company
Last Close Price
8.63
USD
Average target price
7.5
USD
Spread / Average Target
-13.09%
Consensus
1st Jan change
Capi.
+71.91% 5.97B +5.66% 111B +11.23% 105B -2.56% 21.93B -12.15% 22.34B -7.66% 18.59B -36.52% 18.12B -10.09% 16.96B +3.33% 13.7B +36.58% 12.45B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1